Nurix Therapeutics (NRIX) said Thursday that the US Food and Drug Administration has cleared an investigational new drug application for its oral IRAK4 degrader GS-6791/NX-0479, allowing for a phase 1 trial to start, which is expected to begin in Q2.
The company said it is to receive $5 million from Gilead Sciences (GILD) for the IND clearance and remains eligible for up to $420 million in potential future milestone payments as part of a 2019 collaboration agreement.
Nurix said GS-6791/NX-0479 has potential applications in rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis.
Under the terms of the 2019 collaboration agreement, Nurix and Gilead Sciences (GILD) are looking to discover, develop, and commercialize a pipeline of up to five therapies for cancer and other diseases, the company said.
Nurix shares were over 8% higher while Gilead shares were 0.2% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。